AR109209A1 - PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES - Google Patents

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES

Info

Publication number
AR109209A1
AR109209A1 ARP170102166A ARP170102166A AR109209A1 AR 109209 A1 AR109209 A1 AR 109209A1 AR P170102166 A ARP170102166 A AR P170102166A AR P170102166 A ARP170102166 A AR P170102166A AR 109209 A1 AR109209 A1 AR 109209A1
Authority
AR
Argentina
Prior art keywords
prevention
treatment
pharmaceutical composition
neurodegenerative diseases
radotinib
Prior art date
Application number
ARP170102166A
Other languages
Spanish (es)
Inventor
Han Seok Ko
Hyun Soo Ju
Soung Young Kang
Song Ei Song
Hea Un Lee
Gong Yeal Lee
Jae Soo Shin
Sae Bom Lee
Hyo Jung Yun
Hye Lin Park
Jong Seong Park
Choong Am Ahn
Hong Youb Kim
Dae Jin Cho
Dong Yeon Kim
Original Assignee
Il Yang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharm Co Ltd filed Critical Il Yang Pharm Co Ltd
Publication of AR109209A1 publication Critical patent/AR109209A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica para la prevención o el tratamiento de enfermedades neurodegenerativas, que comprende una cantidad eficaz de radotinib o una sal farmacéuticamente aceptable de éste.Pharmaceutical composition for the prevention or treatment of neurodegenerative diseases, which comprises an effective amount of radotinib or a pharmaceutically acceptable salt thereof.

ARP170102166A 2016-08-01 2017-07-31 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES AR109209A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160097863 2016-08-01

Publications (1)

Publication Number Publication Date
AR109209A1 true AR109209A1 (en) 2018-11-07

Family

ID=61073817

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102166A AR109209A1 (en) 2016-08-01 2017-07-31 PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES

Country Status (4)

Country Link
KR (1) KR102421303B1 (en)
AR (1) AR109209A1 (en)
TW (1) TW201808294A (en)
WO (1) WO2018026150A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102618168B1 (en) * 2018-07-06 2023-12-27 일양약품주식회사 Pharmaceutical composition for prevention or treatment of prion disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134922A1 (en) * 2012-05-02 2013-11-07 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
US20140127157A1 (en) * 2012-11-05 2014-05-08 Novartis Ag Antiviral activity of tyrosine kinase inhibitors against hepatitus c virus

Also Published As

Publication number Publication date
WO2018026150A1 (en) 2018-02-08
KR102421303B1 (en) 2022-07-18
TW201808294A (en) 2018-03-16
KR20180015085A (en) 2018-02-12

Similar Documents

Publication Publication Date Title
DOP2020000102A (en) HELPFUL COMPOUNDS TO INHIBIT CDK7
CO2019015090A2 (en) Treatment methods for cystic fibrosis
MX2020013881A (en) Bcl-xl inhibitory compounds and antibody drug conjugates including the same.
DOP2017000178A (en) BACE1 SELECTIVE INHIBITORS
UY37879A (en) BISAMIDE COMPOUNDS THAT ACTIVATE THE SARCOMERO AND ITS USES
CR20160538A (en) COMBINATION
CO2017013293A2 (en) Pharmaceutical formulations comprising tenofovir and emtricitabine
CO2017001875A2 (en) Combination therapy for Alzheimer's using anti-n3pglu antibodies plus a bace inhibitor
MX2021006901A (en) Therapeutic agents for neurodegenerative diseases.
CL2016001587A1 (en) Derivative based on 1,2-naphthoquinone and method of preparation thereof.
CL2016001756A1 (en) Pharmaceutical preparation comprising 0.001-0.003 pv of 6-4-pyrazol-1-ylbenzylpyridin-3-ylsulfonylaminomethylpyridin-2-ylaminoacetate isopropyl or a salt of the same use for the treatment or prevention of glaucoma or ocular hypertension.
CR20150505A (en) DERIVED FROM DIHIDROPIRIDAZIN-3,5-DIONA
SV2016005313A (en) CARBOXAMIDE DERIVATIVES
EP3440094A4 (en) Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
CO2019013254A2 (en) 5,6-fused bicyclic compounds and compositions for the treatment of parasitic diseases
EP3708161A4 (en) Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor
CR20180111A (en) ANTIBACTERIAL AGENTS UNDERSTANDING A PIRAZINO [2,3-B] [1,4] OXAZIN-3-ONA OR A RELATED RING SYSTEM
IT201700121764A1 (en) Composition for the treatment and / or prevention of neurodegenerative diseases.
CR20170125A (en) SOLID PHARMACEUTICAL COMPOSITION INCLUDING AMLODIPINA AND LOSARTÁN
AR109209A1 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASES
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
MX2020003427A (en) Therapeutic agents for neurodegenerative diseases.
BR112018015483A2 (en) stable solid pharmaceutical formulations containing 2- (2-nitro-4-trifluoromethyl-benzoyl) -1,3-cyclohexanedione
CO2020001514A2 (en) Pharmaceutical composition for the prevention or treatment of cardiovascular diseases accompanied by diabetes, including amlodipine, losartan and rosuvastatin, and compound preparation including the same

Legal Events

Date Code Title Description
FB Suspension of granting procedure